Fosifloxuridine Nafalbenamide
Malignant Pleural Mesothelioma
Explore 35 assets in Malignant Pleural Mesothelioma →Floatz Rating
CC40/100
Confidence
Indicative
Sponsor
NuCana plc
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
25Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05714553CT.gov NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Pleural Mesothelioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fosifloxuridine Nafalbenamide (this asset) | NuCana plc | P1/2 | CC · 40 |
| Cis-Diamminedichloroplatinum Ii | AstraZeneca | P2 | BB |
| Carboplatin | AstraZeneca | P2 | BB |
| Pembrolizumab | NuCana plc | P2 | B |
| Fluorouracilum | Memorial Sloan Kettering Cancer Center | P2 | B |
| Atezolizumab | Swiss Cancer Institute | P2 | B |
| Decitabine | National Cancer Institute (NCI) | P1/2 | CCC |
| 68Ga-NOTA-AE105 | Rigshospitalet, Denmark | P2 | CCC |
| Regorafenib | Translational Research in Oncology | P2 | CCC |
+42 more in the Malignant Pleural Mesothelioma cohort
Other indications for Fosifloxuridine Nafalbenamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Neoplasm | — | P2 | CCC · 49 |
| Colorectal Cancer | — | P2 | CC · 43 |
| Colorectal Adenocarcinoma | — | P2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fosifloxuridine Nafalbenamide in Malignant Pleural Mesothelioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fosifloxuridine-nafalbenamide-malignant-pleural-mesothelioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →